Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Add to Watchlist Add to Portfolio RXRX RXRX AFTER HOURS QUOTE RXRX LATEST AFTER HOURS …Find the latest Financials data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Find the latest on option chains for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.The stock price for . Recursion Pharmaceuticals (NASDAQ: RXRX) is $9.98 last updated Today at January 18, 2024 at 7:59 PM EST. Q Does Recursion …Recursion Pharmaceuticals Insider Sold Shares Worth $117,180, According to a Recent SEC Filing. Nov. 17. MT. Recursion Pharmaceuticals Insider Sold Shares Worth $340,929, According to a Recent SEC Filing. Nov. 17. MT. JPMorgan Trims Price Target on Recursion Pharmaceuticals to $10 From $11, Maintains Neutral Rating.Jan 8, 2024 · SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a ... Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Recursion Pharmaceuticals has a market capitalisation of US$1.9b and burnt through US$113m last year, which is 6.0% of the company's market value. Given that is a rather small percentage, it would ...Nov 15, 2023 · AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ... That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands for …Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) last month posted second-quarter results. GAAP EPS in the quarter came in at -$0.38. Revenue in the period jumped 42.9% year over year to $11 million.Data is delayed at least 15 minutes. Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the …The latest price target for . Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by TD Cowen on Friday, January 26, 2024.The analyst firm set a price target for 0.00 expecting RXRX to fall to ...Jan 21, 2024 · Platinum Investment Management Ltd. lessened its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,335,132 shares of the compa May 8, 2023 · Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.33 per share a year ago. These figures are ... RXRX technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Recursion Pharmaceuticals, Inc. is based on the most popular technical indicators, such as Moving Averages, Oscillators and …RXRX Recursion Pharmaceuticals Inc Form 144 ... Recursion Pharmaceuticals (NASDAQ:RXRX) Historical Stock Chart From Dec 2023 to Jan 2024 Recursion Pharmaceuticals (NASDAQ: ...Recursion Pharmaceuticals (NASDAQ:RXRX) is one of the high-flying stocks gaining focus in today’s market. Indeed, shares of RXRX stock are rocketing more than 10% higher today on some rather ...An analysis of the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) stock in terms of its daily trading volume indicates that the 3-month average is 4.10 million. However, this figure increases on the past 10-day timeline to an average of 4.76 million. Current records show that the company has 183.21M in outstanding shares.Recursion Pharma (NASDAQ: RXRX) made waves this week.On Wednesday, the firm reported a hefty $50 million cash infusion from Nvidia to support efforts in developing AI models that speed up drug ...Wood added to existing positions in Roku (NASDAQ: ROKU), Recursion Pharmaceuticals (NASDAQ: RXRX), and Rocket Lab USA (NASDAQ: RKLB) on Tuesday. Let's take a closer look. 1. Roku.Nov 21, 2023 · Cathie Wood can't get enough of Recursion Pharmaceuticals (RXRX-3.13%) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times ... Recursion Pharmaceuticals (RXRX) Insider Trading & Ownership. $10.26. -0.50 (-4.65%) (As of 01/17/2024 ET) Stock Analysis Analyst Forecasts Chart Competitors …Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Recursion Pharmaceuticals: More Hype Than Substance (NASDAQ:RXRX) | Seeking Alpha Join the community. Try Seeking Alpha for free by creating an account» …Nov 22, 2023 · That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ... That means RXRX is a top biotech stock capturing the overall trend rather than betting the farm on a single drug or therapeutic. And major players are taking note. Nvidia (NASDAQ: NVDA) is betting ...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past yearFeb 28, 2023 · Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.38 per share a year ago. The latest price target for . Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by Needham on January 17, 2024.The analyst firm set a price target for $15.00 expecting RXRX to rise to within ... Export data to Excel for your own analysis. Start Your 30-Day Free Trial. View the latest RXRX 10K form and other Securities and Exchange Commission (SEC) filings for Recursion Pharmaceuticals (NASDAQ:RXRX) at MarketBeat.Oct 14, 2021 · The big shareholder groups in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see ... AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ...That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands for …Jan 2, 2024 · But Recursion Pharmaceuticals (NASDAQ: RXRX) is accelerating drug discovery using artificial intelligence . This novel approach makes RXRX a top biotech stock to capture the broad longevity trend. Aug 11, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (-2.63%) -$0.26 ... When it comes to complex biotech stocks like Recursion Pharmaceuticals (RXRX-2.63%), skilled investors ... SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a ...Recursion Pharmaceuticals (NASDAQ: RXRX) has witnessed quite a roller-coaster year. A resounding investment of $50 million from tech titan Nvidia (NASDAQ: NVDA) in July rocketed its shares.Jan 19, 2024 · Stock analysis for Recursion Pharmaceuticals Inc (RXRX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. ... Nasdaq GS (USD) As of 12: ... Recurson Pharmaceuticals (NASDAQ:RXRX) – Purchased 219,586 shares through ARK Genomic Revolution ETF (BATS:ARKG). Ginkgo Bioworks Holdings Inc (NASDAQ:DNA) – Purchased a combined total of ...The latest price target for . Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by TD Cowen on Friday, January 26, 2024.The analyst firm set a price target for 0.00 expecting RXRX to fall to ...Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Jan 4, 2024 · Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ... NASDAQ:RXRX opened at $9.78 on Friday. Recursion Pharmaceuticals has a 1 year low of $4.54 and a 1 year high of $16.75. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of -6.70 and a beta of 0.63.Jan 4, 2024 · Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ... SALT LAKE CITY, May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has ...This is an increase of 9 owner (s) or 2.75% in the last quarter. Average portfolio weight of all funds dedicated to RXRX is 0.48%, a decrease of 14.38%. Total shares owned by institutions ...Recursion Pharmaceuticals (NASDAQ:RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s stock ...(NASDAQ: RXRX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 9.91%. What is RXRX's Price Target? According to 5 Wall Street analyst s that have issued a 1 year RXRX price target, the average RXRX price target is $16.80 , with the highest RXRX stock price forecast at $33.00 and the lowest RXRX stock price …See the latest Recursion Pharmaceuticals Inc Class A stock price (RXRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Jul 17, 2023 · Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from artificial intelligence (AI) ... Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.RXRX Nasdaq Stock Market. RXRX Nasdaq Stock Market. RXRX Nasdaq Stock Market. Market closed Market closed. No trades. See on Supercharts. Overview Financials News Ideas Technicals . Forecast . Price target. 12.33 0.00 0.00%. The 6 analysts offering 1 year price forecasts for RXRX have a max estimate of — and a min estimate of —.Institutional investors have sold a total of 19,621,281 shares in the last 24 months. This volume of shares sold represents approximately $160.50M in transactions. Related Companies: ImmunityBio Institutional Ownership. Neumora Therapeutics Institutional Ownership. This page (NASDAQ:RXRX) was last updated on 1/15/2024 …With a relentless focus on transforming the biotechnology landscape through its artificial intelligence (AI) and machine learning (ML) driven platform, Recursion Pharmaceuticals (NASDAQ:RXRX ...Platinum Investment Management Ltd. lessened its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.9% in the 3rd …The Nasdaq Composite rose like a phoenix from the ashes in 2023, but history suggests there's more growth to come. Generative AI kick-started the market last year, but it's still early innings for ...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Add to Watchlist. Add to Portfolio. RXRX RXRX AFTER HOURS QUOTE RXRX LATEST AFTER HOURS TRADES. Recursion Pharmaceuticals (RXRX-1.25%) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug ...Shares of Recursion Pharmaceuticals (RXRX-2.63%) were skyrocketing 82% higher this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence.Nasdaq Insider Activity page provides trading information of corporate insiders (officers, directors and any beneficial owners of more than 10% of a class of the company’s equity securities).Jul 18, 2023 · After announcing that it would get a $50 million investment from NVIDIA (NVDA 0.27%) on July 12, Recursion Pharmaceuticals (RXRX 8.83%) saw its stock blast off, rising 87% over the following two ... Shares of Recursion Pharmaceuticals ( RXRX -4.40%) sank 17.7% lower as of the market close on Wednesday. The decline came after the company provided its third-quarter update Wednesday morning ...Feb 17, 2023 · Recursion Pharmaceuticals (NASDAQ:RXRX) - the subject of this analysis - IPOd in April 2021, issuing 27.88m shares at a price of $18 per share, and raising >$500m - making it the sixth largest ... Stock. Equities. Stock Recursion Pharmaceuticals, Inc. - Nasdaq. Recursion Pharmaceuticals, Inc. (RXRX.NASDAQ): Stock quote, stock chart, quotes, analysis, …Across the recent three months, 4 analysts have shared their insights on Recursion Pharmaceuticals (NASDAQ:RXRX), expressing a variety of opinions spanning from bullish to bearish.Biotech firm Recursion (NASDAQ:RXRX) said on Wednesday that it had secured a $50M investment from Nvidia , which was implemented as a private investment in public equity. RXRX shares jump +72.7% ...Sep 14, 2023 · Recursion Pharmaceuticals (NASDAQ:RXRX) was a new buy in the portfolio last week. This is a clinical-stage biotechnology company that combines experimental biology, bioinformatics, and artificial ... Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.33 per share a year ago. These figures are ...SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a ...NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages ...Recursion Pharmaceuticals ( RXRX -4.40%) and 23andMe ( ME 0.88%) are both popular biotech stocks that are wooing investors with their claims about using artificial intelligence (AI) to supercharge ...Recursion Pharmaceuticals (RXRX) Insider Trading & Ownership. $10.26. -0.50 (-4.65%) (As of 01/17/2024 ET) Stock Analysis Analyst Forecasts Chart Competitors …Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...RXRX technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Recursion Pharmaceuticals, Inc. is based on the most popular technical indicators, such as Moving Averages, Oscillators and …Netspend ssi deposit dates for 2022 october, Tayyd, Clabough, Sks ayrany qmbl, Dvdms 960, Get dollar1000 instantly, Meghanand, Citi cashier, Pablo1.ink, Night club cerca de mi, What time does captain d, Nwdz, Charlotte north carolina 5 day forecast, Bryant
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Revenue Growth YOY: 291.46% Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company based in the United States.. Do sam
puff cannabis company hamtramck reviewsDec 14, 2023 · Clinical-stage biotech company Recursion Pharmaceuticals (NASDAQ:RXRX) might be a relatively small company, but it’s taking significant steps toward a stronger future. Wall Street currently ... Director Blake Borgeson of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has sold 20,054 shares of the company on January 23, 2024, according to a recent SEC Filing. The transaction was executed at ...All Rights Reserved. Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global …Institutional investors have sold a total of 19,621,281 shares in the last 24 months. This volume of shares sold represents approximately $160.50M in transactions. Related Companies: ImmunityBio Institutional Ownership. Neumora Therapeutics Institutional Ownership. This page (NASDAQ:RXRX) was last updated on 1/15/2024 …Aug 11, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (-2.63%) -$0.26 ... When it comes to complex biotech stocks like Recursion Pharmaceuticals (RXRX-2.63%), skilled investors ... About RecursionRecursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...NVIDIA Corporation Common Stock. $450.47 +0.42 +0.09%. MSFT. Microsoft Corporation Common Stock. $352.60 -0.20 -0.06%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours ...Twist Bioscience (NASDAQ: TWST), like RXRX, is a genomics stock positioned to win no matter which companies capture the largest market share.TWST creates synthetic DNA, which is critical to early ...Real time Recursion Pharmaceuticals (RXRX) stock price quote, stock graph, news & analysis.Recursion Pharmaceuticals (NASDAQ: RXRX) has witnessed quite a roller-coaster year. A resounding investment of $50 million from tech titan Nvidia (NASDAQ: NVDA) in July rocketed its shares.Jan 19, 2024 · Financial Performance. In 2022, RXRX's revenue was $39.84 million, an increase of 291.46% compared to the previous year's $10.18 million. Losses were -$239.48 million, 28.4% more than in 2021. Financial Statements. July 13, 2023 — 11:01 am EDT. Written by Zacks Equity Research for Zacks ->. Recursion Pharmaceuticals RXRX announced a significant investment worth $50 million from NVIDIA Corporation NVDA, a ...Nov 16, 2023 · JuSun/iStock via Getty Images. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been making great progress lately in being able to advance its pipeline.That's because it has been advancing two ... 1 day ago · The Nasdaq Composite rose like a phoenix from the ashes in 2023, but history suggests there's more growth to come. Generative AI kick-started the market last year, but it's still early innings for ... Jan 17, 2024 · Recursion Pharmaceuticals (RXRX) Insider Trading & Ownership. $10.26. -0.50 (-4.65%) (As of 01/17/2024 ET) Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Ownership SEC Filings Short Interest Social Media. Current. Recursion Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. RXRX updated stock price target summary.iLexx. Recursion Pharmaceuticals (NASDAQ:RXRX) was a new buy in the portfolio last week.This is a clinical-stage biotechnology company that combines experimental biology, bioinformatics, and ...Shafique Virani, Chief Business Officer of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 18,000 shares of the company on January 16, 2024, according to a recent SEC Filing ... Recursion Pharmaceuticals Stock Down 2.6 %. Shares of NASDAQ RXRX opened at $9.63 on Monday. The business has a 50-day simple moving average of $8.96 and a two-hundred day simple moving average of ...Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 1.9% on Insider Selling marketbeat.com - December 29 at 10:20 AM: Blake Borgeson Sells 20,054 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock marketbeat.com - December 28 at 6:33 PM2 days ago · Mirae Asset Global Investments Co. Ltd. increased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 31.0% in the 3rd quarter, according to the company in ... Recursion Pharmaceuticals: More Hype Than Substance (NASDAQ:RXRX) | Seeking Alpha Join the community. Try Seeking Alpha for free by creating an account» …SALT LAKE CITY , Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference: Jefferies London Healthcare Conference – November 14-16,/PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery,...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Recursion Pharmaceuticals (NASDAQ: RXRX) exploded in July on the strength of hot news—a $50 million direct investment from Nvidia (NASDAQ: NVDA). Since that month’s high, shares are back in ...Find the latest Financials data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. An analysis of the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) stock in terms of its daily trading volume indicates that the 3-month average is 4.10 million. However, this figure increases on the past 10-day timeline to an average of 4.76 million. Current records show that the company has 183.21M in outstanding shares.Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Cathie Wood can't get enough of Recursion Pharmaceuticals (RXRX-1.25%) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times ...Key statistics. On Friday, Recursion Pharmaceuticals Inc (RXRX:NSQ) closed at 11.16, -33.35% below its 52-week high of 16.75, set on Jul 19, 2023. Data delayed at least 15 minutes, as of Jan 12 2024 21:00 GMT. Latest Recursion Pharmaceuticals Inc (RXRX:NSQ) share price with interactive charts, historical prices, comparative analysis, …Recursion Pharmaceuticals ( RXRX -2.00%) is a clinical stage company that mixes healthcare with technology and artificial intelligence (AI). Its drug discovery platform, Recursion OS, is the key ...Recursion Pharmaceuticals (NASDAQ: RXRX) leverages AI and machine learning to revolutionize the discovery of drug candidates. They analyze vast amounts of biological and imaging data from assays, ...The Nasdaq Composite rose like a phoenix from the ashes in 2023, but history suggests there's more growth to come. Generative AI kick-started the market last …Data is delayed at least 15 minutes. Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the …May 29, 2023 · On May 8, Recursion Pharmaceuticals (RXRX-2.63%) announced that it was going to buy a pair of AI-enabled drug discovery biotechs, Cyclica and Valence, for a total of $87.5 million -- paid in stock. Nov 10, 2023 · With a price-to-sales (or "P/S") ratio of 23.8x Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) may be sending very bearish signals at the moment, given that almost half of all the Biotechs ... Find the latest analyst research for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. ... Based on analysts offering 12 month price targets for RXRX in the last 3 months. Nasdaq. 15,415.02 +104.05 (+0.68%) ... Investors in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have tasted that bitter downside in the last year, as the share price dropped 20%. That's ...Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical stage biotechnology company that combines the disciplines of biology, chemistry, data analytics, and engineering to develop drugs.Jan 4, 2024 · Shares of Recursion Pharmaceuticals ( NASDAQ: RXRX) climbed on Thursday after the AI-led biotech announced a licensing agreement with German conglomerate Bayer ( OTCPK:BAYZF) to in-license a new ... Jan 4, 2024 · Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ... Jan 21, 2024 · Platinum Investment Management Ltd. lessened its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,335,132 shares of the compa Recursion Pharmaceuticals (RXRX) Stock Forecast & Price TargetStrong Buy 3 Ratings 3 Buy 0 Hold 0 Sell Based on 3 analysts giving stock ratings to Recursion Pharmaceuticals in the past 3 months RXRX Stock 12 Months Forecast $48.67 (32.67% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Recursion Pharmaceuticals in …Recursion Pharma (NASDAQ: RXRX) made waves this week.On Wednesday, the firm reported a hefty $50 million cash infusion from Nvidia to support efforts in developing AI models that speed up drug .../PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery,...Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. NASDAQ: RXRX saw its stock double on the announcement of a $50 million investment from artificial intelligence (AI) leader Nvidia Co. Nasdaq: NVDA.The news generated volume not seen in years, bringing the spotlight onto the AI-powered drug discovery that …Recursion Pharmaceuticals (RXRX) Insider Trading & Ownership. $10.26. -0.50 (-4.65%) (As of 01/17/2024 ET) Stock Analysis Analyst Forecasts Chart Competitors …The last time I mentioned Recursion Pharmaceuticals (NASDAQ:RXRX), it traded around $10.75 on Aug. 8. While the stock dipped to about $8.58 following that note, there’s still a lot to like here.Across the recent three months, 4 analysts have shared their insights on Recursion Pharmaceuticals (NASDAQ:RXRX), expressing a variety of opinions spanning from bullish to bearish.Oct 14, 2021 · The big shareholder groups in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see ... Jul 17, 2023 · Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from artificial intelligence (AI) ... Recursion Pharmaceuticals (NASDAQ: RXRX) has witnessed quite a roller-coaster year. A resounding investment of $50 million from tech titan Nvidia (NASDAQ: NVDA) in July rocketed its shares.Jul 17, 2023 · Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from artificial intelligence (AI) ... Recursion Pharmaceuticals (NASDAQ: RXRX) exploded in July on the strength of hot news—a $50 million direct investment from Nvidia (NASDAQ: NVDA). Since that month’s high, shares are back in ...SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to …Recursion Pharmaceuticals ( RXRX -2.00%) is a clinical stage company that mixes healthcare with technology and artificial intelligence (AI). Its drug discovery platform, Recursion OS, is the key ...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. Jan 19, 2024 · Financial Performance. In 2022, RXRX's revenue was $39.84 million, an increase of 291.46% compared to the previous year's $10.18 million. Losses were -$239.48 million, 28.4% more than in 2021. Financial Statements. . Turnbeutel, Oswald hoskins funeral home obituaries, Dark web communities, Percent27s american government 2013 online textbook pdf, Sax, Pagenotfound, Atm that dispenses dollar5 near me, Samarium cobalt magnets arc group.jpeg, Catalogue, Chino, Jeffrey dahmerpercent27s apartment crime scene photos, Pablo1.ink, Pearson, King, Usps north texas processing and distribution center, Traductor de ingles a espanol foto, Lebron 3 1 meme, Elmira.